霉酚酸酯治疗重症肌无力后发生的T细胞淋巴增殖性疾病
T-cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gravis.
作者信息
Dubal Dena B, Mueller Sabine, Ruben Beth S, Engstrom John W, Josephson S Andrew
机构信息
Department of Neurology, University of California at San Francisco, 505 Parnassus Avenue, Box 0114, San Francisco, California 94143, USA.
出版信息
Muscle Nerve. 2009 Jun;39(6):849-50. doi: 10.1002/mus.21306.
Immunosuppressive therapies are critical in the management of numerous conditions including myasthenia gravis. Mycophenolate mofetil is a widely used, oral immunosuppressive agent that is considered to have few adverse effects compared with similar drugs. We report the case of a patient who developed T-cell lymphoproliferative lesions following long-term treatment with mycophenolate mofetil and prednisone for myasthenia gravis. The lesions resolved following cessation of the treatment. This case highlights a serious complication of a commonly used drug.
免疫抑制疗法在包括重症肌无力在内的多种病症的治疗中至关重要。霉酚酸酯是一种广泛使用的口服免疫抑制剂，与同类药物相比，其副作用被认为较少。我们报告了一例患者，该患者在长期使用霉酚酸酯和泼尼松治疗重症肌无力后出现了T细胞淋巴增殖性病变。停药后病变消退。该病例凸显了一种常用药物的严重并发症。
Zotero 插件